Sarcoidosis is a complex disease with autoimmune basis and still unknown etiology. We have screened for mutations in the cystic fibrosis conductance regulator (CFTR) gene and genotyped single-nucleotide polymorphisms in the tumor necrosis factor (TNF), interferon alpha-10 (IFNA10), IFNA17, and interferon gamma (IFNG) genes in 89 Greek patients with sarcoidosis and 212 control subjects to detect possible association between them and the risk for developing sarcoidosis. We have found a statistically significant increase (p = 6.1 × 10−8) of CFTR mutation carriers in the population of patients with sarcoidosis versus the control population. A difference was also noted within the group of patients with sarcoidosis where the ones with CFTR mutations suffered more frequently from dyspnea than those without (p = 5 × 10−6). Our study did not reproduce the associations previously noted with the TNF, IFNA10, IFNA17, and IFNG genes, which highlights the genetic complexity of the disorder and is in agreement with previous studies showing that CFTR might be an important factor in the clinical course of the disease.
Get full access to this article
View all access options for this article.
References
1.
ACCESS Research Group. 1999. Design of a case control etiologic study of sarcoidosis (ACCESS)J Clin Epidemiol, 52:1173-1186.
2.
AkahoshiMet al.2004. Association between IFNA genotype and the risk of sarcoidosis. Hum Genet, 114:503-509.
3.
AntoniouKMet al.2006. Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. J Interferon Cytokine Res, 26:400-405.
4.
[ATS, ERS, WASOG]. 1999. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med, 160:736-755.
5.
BaughmanRPet al.2006. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med, 174:795-802.
6.
BaughmanRP, LowerEE, du BoisRM. 2003. Sarcoidosis. Lancet, 361:1111-1118.
7.
BombieriCet al.1998. Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum Genet, 103:718-722.
8.
BombieriCet al.2000. Increased frequency of CFTR gene mutations in sarcoidosis: a case/control association study. Eur J Hum Genet, 8:717-720.
9.
BombieriCet al.2003. Comment on “CFTR gene mutations in sarcoidosis.”Eur J Hum Genet, 11:553-554.
10.
BoumaGet al.1996. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol, 43:456-463.
11.
BrewertonDAet al.1977. HLA antigens in sarcoidosis. Clin Exp Immunol, 27:227-229.
12.
CastellaniCet al.2008. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros, 7:179-196.
13.
CelikGet al.2005. Sarcoidosis caused by interferon therapy. Respirology, 10:535-540.
14.
CostabelU, HunninghakeGW. 1999. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J, 14:735-737.
15.
DorkTet al.1997. Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet, 100:365-377.
DubaniewiczAet al.2005. Association between SLC11A1 (formerly NRAMP1) and the risk of sarcoidosis in Poland. Eur J Hum Genet, 13:829-834.
18.
FanenPet al.1992. Molecular characterization of cystic fibrosis: 16 novel mutations identified by analysis of the whole cystic fibrosis conductance transmembrane regulator (CFTR) coding regions and splice site junctions. Genomics, 13:770-776.
19.
Ferrer-CostaC, OrozcoM, de la CruzX. 2004. Sequence-based prediction of pathological mutations. Proteins, 57:811-819.
20.
FrankeAet al.2008. Genome-wide association analysis in sarcoidosis and Crohn's disease unravels a common susceptibility locus on 10p12.2. Gastroenterology, 135:1207-1215.
21.
FriedmanKJet al.1997. Rapid characterization of the variable length polythymidine tract in the cystic fibrosis (CFTR) gene: association of the 5T allele with selected CFTR mutations and its incidence in atypical sinopulmonary disease. Hum Mutat, 10:108-115.
22.
FuruyaKet al.1996. Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Thorax, 51:777-780.
23.
GoldbergJB, PierGB. 2000. The role of the CFTR in susceptibility to Pseudomonas aeruginosa infections in cystic fibrosis. Trends Microbiol, 8:514-520.
24.
GreeneCMet al.2000. Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis. J Immunol, 165:4718-4724.
25.
GruttersJCet al.2002. Increased frequency of the uncommon tumor necrosis factor −857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med, 165:1119-1124.
26.
HillTAet al.2008. Intracellular cytokine profiles and T cell activation in pulmonary sarcoidosis. Cytokine, 42:289-292.
27.
HiranoAet al.2005. Sarcoidosis occurring after interferon-alpha therapy for chronic hepatitis C: report of two cases. Respirology, 10:529-534.
28.
HoLPet al.2005. CARD 15 gene mutations in sarcoidosis. Thorax, 60:354-355.
29.
HofmannSet al.2008. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet, 40:1103-1106Erratum in: Nat Genet 2009;41:504.
30.
HunninghakeGWet al.1999. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis, 16:149-173.
31.
IannuzziMC, RybickiBA, TeirsteinAS. 2007. Sarcoidosis. N Engl J Med, 357:2153-2165.
32.
JosephFG, ScoldingNJ. 2007. Sarcoidosis of the nervous system. Pract Neurol, 7:234-244.
33.
KanavakisEet al.1998. Cystic fibrosis mutation screening in CBAVD patients and men with obstructive azoospermia or severe oligozoospermia. Mol Hum Reprod, 4:333-337.
34.
KanavakisEet al.2003. Cystic fibrosis in Greece: molecular diagnosis, haplotypes, prenatal diagnosis and carrier identification amongst high-risk individuals. Clin Genet, 63:400-409.
PaganiFet al.2003. New type of disease causing mutations: the example of the composite exonic regulatory elements of splicing in CFTR exon 12. Hum Mol Genet, 12:1111-1120.
43.
PapatheodorouAet al.2007. Development of a novel microarray methodology for the study of SNPs in the promoter region of the TNF-alpha gene: their association with obstructive pulmonary disease in Greek patients. Clin Biochem, 40:843-850.
44.
PetrekMet al.2000. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med, 162,3 Pt 1:1000-1003.
45.
PierGB. 1997. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients. Behring Inst Mitt, 98:350-360.
46.
PierGB, GroutM, ZaidiTS. 1997. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci U S A, 94:12088-12093.
47.
PurcellSet al.2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet, 81:559-575.
48.
RamenskyV, BorkP, SunyaevS. 2002. Human non-synonymous SNPs: server and survey. Nucleic Acids Res, 30:3894-3900.
49.
RoseAS, TielkerMA, KnoxKS. 2008. Hepatic, ocular, and cutaneous sarcoidosis. Clin Chest Med, 29:509-524, ix.
50.
RosenY. 2007. Pathology of sarcoidosis. Semin Respir Crit Care Med, 28:36-52.
51.
RossmanMD, KreiderME. 2007. Lesson learned from ACCESS (A Case Controlled Etiologic Study of Sarcoidosis)Proc Am Thorac Soc, 4:453-456.
52.
SchoenbornJR, WilsonCB. 2007. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol, 96:41-101.
SeyhanECet al.2008. Vascular endothelial growth factor and tumor necrosis factor genes polymorphisms in Turkish patients with sarcoidosis. Tuberk Toraks, 56:5-14.
56.
SharmaS, GhoshB, SharmaSK. 2008. Association of TNF polymorphisms with sarcoidosis, its prognosis and tumour necrosis factor (TNF)-alpha levels in Asian Indians. Clin Exp Immunol, 151:251-259.
57.
StephensM, DonnellyP. 2003. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet, 73:1162-1169.
58.
StephensM, SmithNJ, DonnellyP. 2001. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet, 68:978-989.
59.
TzetisMet al.2001. CFTR gene mutations—including three novel nucleotide substitutions—and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet, 108:216-221.
60.
TzetisMet al.2007. Contribution of the CFTR gene, the pancreatic secretory trypsin inhibitor gene (SPINK1) and the cationic trypsinogen gene (PRSS1) to the etiology of recurrent pancreatitis. Clin Genet, 71:451-457.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
